Fibrogen announces topline results from phase 1 monotherapy study of fg-3246 in patients with metastatic castration-resistant prostate cancer

San francisco, april 02, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced topline data from the fortis therapeutics-sponsored phase 1 study of fg-3246 (also known as for46), a potential first-in-class anti-cd46 antibody drug conjugate (adc) with an mmae-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer (mcrpc) whose tumors have progressed on at least one androgen receptor-signaling inhibitor (arsi).
FGEN Ratings Summary
FGEN Quant Ranking